secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0000950170-22-026551
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics appoints Laura Berner to Board of Directors
----------------------------------------------------------------

- Board expanded from 9 to 10; Laura Berner appointed as Class I director, term through 2025 annual meeting.
- Berner qualifies as independent under Nasdaq rules; no reportable related-party transactions.
- Received initial option award for 50,000 shares, vesting over 36 months, and prorated option for 12,261 shares.
- Eligible for annual option of 25,000 shares and $35,000 cash retainer under non-employee director compensation policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022026551/0000950170-22-026551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022026551/bolt-20221214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer